Multiple clinical studies have found that TP53 co-mutation is a poor prognostic marker for EGFR-mutated NSCLC and a predictor of poor clinical outcomes for EGFR-TKI treatment (54). Here, EGFR is linked to non-small cell lung carcinoma.